Artrya Ltd has released a press release.
Mass General Brigham to Participate in SAPPHIRE Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Artrya
- Completion of Placement and Cleansing Notice
- Completion of Share Purchase Plan
- Successful A$75 million placement and launch of SPP
- Trading Halt
- FDA clearance of Salix® Coronary Plaque module
Later from Artrya
- SAPPHIRE Study Expands With Inclusion of Ascension
- S&P DJI Announces December 2025 Quarterly Rebalance
- Second US Commercial Customer - Northeast Georgia
- First Revenues from Salix Coronary Plaque Module
- Cone Health Becomes Third U.S. Customer
Follow Artrya into a list and get an email when it puts out news.
Follow Artrya